A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence - Summary - MDSpire

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence

  • By

  • Jonathan I. Silverberg

  • Alan D. Irvine

  • Peter Foley

  • James Del Rosso

  • Luis Puig

  • Linda Stein Gold

  • Masahiro Kamata

  • Andreas Wollenberg

  • H. Chih-ho Hong

  • Chia-Yu Chu

  • Yousef Binamer

  • Martin Dossenbach

  • Marta Casillas

  • Gaia Gallo

  • Buelent Akmaz

  • Kim Rand

  • Raj Chovatiya

  • June 17, 2026

  • 0 min

Share

Objective:

To compare the long-term efficacy of lebrikizumab, dupilumab, and tralokinumab in atopic dermatitis, with a specific focus on the impact of treatment adherence and the off-drug durability of response on overall efficacy.

Key Findings:
  • Lebrikizumab demonstrated comparable or superior long-term efficacy compared to dupilumab and superior efficacy compared to tralokinumab, though findings regarding the Durability Index (DI) should be interpreted with caution and require independent validation.
Interpretation:

The study offers a new perspective on the long-term performance of biologics in atopic dermatitis, highlighting the critical role of treatment adherence in achieving sustained efficacy.

Limitations:
  • The DI is a novel measure that necessitates further validation.
  • The analysis is based on data from different trials with varying populations, which may introduce biases.
Conclusion:

This study is the first to apply the Durability Index in an indirect comparative analysis of these biologics, with potential implications for clinical decision-making.

Original Source(s)

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence

  • by Jonathan I. Silverberg, Alan D. Irvine, Peter Foley, James Del Rosso, Luis Puig, Linda Stein Gold, Masahiro Kamata, Andreas Wollenberg, H. Chih-ho Hong, Chia-Yu Chu, Yousef Binamer, Martin Dossenbach, Marta Casillas, Gaia Gallo, Buelent Akmaz, Kim Rand, Raj Chovatiya

  • June 17, 2026

Related Content

The traditional Chinese medicine bloodletting therapy at the Taiyang acupoint (No.EX-HN5) for the treatment of periorbital venous malformation: a case report

Clinical and imaging features of tufted angioma in children

Targeted replacement of human γδ TCR in mice enhances antigen-specific B cell immunity